PPARδ agonists might modulate the development ofatherosclerosis and acute coronary syndrome, not only by targeting foam cellsand lipoprotein metabolism [56, 57], or protecting against obesity [58], butalso by promoting endothelial cell survival via 14-3-3ε [34]. Here, PPARD is linked to obesity due to melanocortin 4 receptor deficiency.